Firstly, I can’t tell you how good it is to see investors actually talking about the clinical trials instead of charts and fractals. I’m so sick of all the screen junkie behavior.
At the end of the day it will be the IP development that will deliver shareholder value. Always has been, always will be.
In contemplating your comment though, I imagine isoflurane is part of the answer as this has an impact on the BBB permeability.
IHL Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
